Fragment-based QSAR: perspectives in drug design

被引:0
|
作者
Lívia B. Salum
Adriano D. Andricopulo
机构
[1] Universidade de São Paulo,Laboratório de Química Medicinal e Computacional, Centro de Biotecnologia Molecular Estrutural, Instituto de Física de São Carlos
来源
Molecular Diversity | 2009年 / 13卷
关键词
Drug design; SAR; QSAR; Fragment-based; Pharmacodynamics; Pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
Drug design is a process driven by innovation and technological breakthroughs involving a combination of advanced experimental and computational methods. A broad variety of medicinal chemistry approaches can be used for the identification of hits, generation of leads, as well as to accelerate the optimization of leads into drug candidates. Quantitative structure–activity relationship (QSAR) methods are among the most important strategies that can be applied for the successful design of small molecule modulators having clinical utility. Hologram QSAR (HQSAR) is a modern 2D fragment-based QSAR method that employs specialized molecular fingerprints. HQSAR can be applied to large data sets of compounds, as well as traditional-size sets, being a versatile tool in drug design. The HQSAR approach has evolved from a classical use in the generation of standard QSAR models for data correlation and prediction into advanced drug design tools for virtual screening and pharmacokinetic property prediction. This paper provides a brief perspective on the evolution and current status of HQSAR, highlighting present challenges and new opportunities in drug design.
引用
收藏
页码:277 / 285
页数:8
相关论文
共 50 条
  • [41] MolOptimizer: A Molecular Optimization Toolkit for Fragment-Based Drug Design
    Soffer, Adam
    Viswas, Samuel Joshua
    Alon, Shahar
    Rozenberg, Nofar
    Peled, Amit
    Piro, Daniel
    Vilenchik, Dan
    Akabayov, Barak
    [J]. MOLECULES, 2024, 29 (01):
  • [42] The multiple roles of computational chemistry in fragment-based drug design
    Richard Law
    Oliver Barker
    John J. Barker
    Thomas Hesterkamp
    Robert Godemann
    Ole Andersen
    Tara Fryatt
    Steve Courtney
    Dave Hallett
    Mark Whittaker
    [J]. Journal of Computer-Aided Molecular Design, 2009, 23 : 459 - 473
  • [43] A computational protocol to fragment-based drug design at PDB scale
    F Moriaud
    T Henry
    SA Adcock
    AM Vorotynsev
    L Martin
    O Doppelt
    AG De Brevern
    F Delfaud
    [J]. Chemistry Central Journal, 2 (Suppl 1)
  • [44] Fragment-based drug design: How big is too big?
    Hajduk, Philip J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (24) : 6972 - 6976
  • [45] Fragment-based drug design facilitates selective kinase inhibitor
    Wang, Zhi-Zheng
    Shi, Xing-Xing
    Huang, Guang-Yi
    Hao, Ge-Fei
    Yang, Guang-Fu
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2021, 42 (07) : 551 - 565
  • [46] Interfacial logP in structural fragment-based QSAR models
    Rathman, James F.
    Yang, Chihae
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232 : 368 - 368
  • [47] A new software for fragment-based QSAR and its applications
    Sergey B Sosnin
    Vladimir A Palyulin
    Nikolay S Zefirov
    [J]. Journal of Cheminformatics, 6 (Suppl 1)
  • [48] Library Design Strategies To Accelerate Fragment-Based Drug Discovery
    Troelsen, Nikolaj S.
    Clausen, Mads H.
    [J]. CHEMISTRY-A EUROPEAN JOURNAL, 2020, 26 (50) : 11391 - 11403
  • [49] Fragment-based drug design of nature-inspired compounds
    Najjar, Abdulkarim
    Olgac, Abdurrahman
    Ntie-Kang, Fidele
    Sippl, Wolfgang
    [J]. PHYSICAL SCIENCES REVIEWS, 2019, 4 (09)
  • [50] Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD)
    Palmer, Nick
    Peakman, Torren M.
    Norton, David
    Rees, David C.
    [J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2016, 14 (05) : 1599 - 1610